Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

PURPOSE: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (NCCN)/European Society for Medical Oncology (ESMO)...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowakowski, Grzegorz S., Yoon, Dok Hyun, Peters, Anthea, Mondello, Patrizia, Joffe, Erel, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Huang, Dan, Waltl, Eva E., Winderlich, Mark, Kurukulasuriya, Nuwan C., Ambarkhane, Sumeet, Hess, Georg, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475241/
https://www.ncbi.nlm.nih.gov/pubmed/35674661
http://dx.doi.org/10.1158/1078-0432.CCR-21-3648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475241/
https://www.ncbi.nlm.nih.gov/pubmed/35674661
http://dx.doi.org/10.1158/1078-0432.CCR-21-3648

Ejemplares similares